INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES
-
![GettyImages-1691974990-exosome-3d-render-cell]( "Uncovering The Potential Of Exosomes")
Uncovering The Potential Of ExosomesExosomes show early promise as drugs and drug carriers, but limited understanding of how their characteristics relate to function complicates isolating specific populations and scaling production.
-
![iStock-1213713667-viral-vector-virus]( "Viral Vector Production: How CDMOs Influence Late-Stage Development Success")
Viral Vector Production: How CDMOs Influence Late-Stage Development SuccessLate-stage viral vector programs leave almost no margin for error. Regulatory, operational, and market pressures shape the path to commercial launch, and the choice of manufacturing partner carries real weight.
-
![Lipid Nanoparticles GettyImages-1437855772]( "Top 5 Things To Know About The Lipid Nanoparticle Portfolio")
Top 5 Things To Know About The Lipid Nanoparticle PortfolioLipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.
-
![cell culture, medicine, medical, laboratory-GettyImages-1491010530]( "Avoiding The Pitfalls: 5 Lessons For Cell Therapy Manufacturing Success")
Avoiding The Pitfalls: 5 Lessons For Cell Therapy Manufacturing SuccessCell therapy programs often stall between clinical and commercial supply because of manufacturing readiness, not clinical performance. Five recurring pitfalls, from partner choice to automation, show where early planning matters.
-
![autoimmne panel people]( "Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026")
Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026At Meeting on the Mesa 2026, industry leaders discussed what it will take to move autoimmune CAR T beyond promising clinical results.
-
![Bridging Binder Discovery And Automated CAR T Cell Manufacturing]( "Bridging Binder Discovery And Automated CAR T Cell Manufacturing")
Bridging Binder Discovery And Automated CAR T Cell ManufacturingCLDN6-targeting CAR T cells for solid tumors move from binder discovery through manufacturing, with attention to how process design shapes technology transfer and consistency.
-
![GettyImages-1213787059-scientist-in-laboratory-with-flasks-cell-culture]( "Building The Infrastructure Behind Cell Therapy Manufacturing")
Building The Infrastructure Behind Cell Therapy ManufacturingA small automation shop focused on cell therapy manufacturing grew into a platform covering equipment, consumables, software, and industrialization services for commercial-scale production runs.
-
![26_09_CGL_Seg03]( "Scaling Cryopreservation Without Wasting MSC Product")
Scaling Cryopreservation Without Wasting MSC ProductDuring this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. turn the discussion to the practical challenges of cryopreserving large cell volumes, manufacturing capacity, and how companies can avoid introducing major changes as they move toward commercialization.
-
![26_09_CGL_Seg07]( "When Small Process Changes Become A Different MSC Product")
When Small Process Changes Become A Different MSC ProductDuring this final segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. cover a particularly strong manufacturing point. Even seemingly minor changes in cell culture, processing, or expansion can accumulate and create product drift, raising the question of when a modified process produces what is effectively a different cell therapy.
-
![Doctor holding patients hands-GettyImages-474808854]( "What LSPA's Life Sciences Future Says About The Road Ahead For CGT")
What LSPA's Life Sciences Future Says About The Road Ahead For CGTThe LSPA’s Life Sciences Future 2026 highlighted how shifting capital, M&A, global competition, and commercial pressures are reshaping CGT.
